



Adolore Biotherapeutics to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Tuesday, July 11th at 4:00 PM ET

DELRAY BEACH, FL. – July 5, 2023 – Adolore Biotherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for pain, today announced that [Roelof Rongen, CEO and Roy Levitt, MD, Founder and Executive Chairman of Adolore](#), will participate in the [Virtual Investor Summer Spotlight Series](#) on Tuesday, July 11, 2023 at 4:00 PM ET.

A [live video webcast](#) of the presentation will be accessible on the event website, [virtualinvestco.com](#). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Adolore Biotherapeutics

Adolore Biotherapeutics, Inc., is a biotechnology company focused on developing novel therapies for the treatment of chronic pain and other pain and nervous system conditions or disorders. Our best-in-class programs are long-acting, locally-acting gene therapies that are opioid-free Disease Modifying Anti-Pain therapies (DMAPs) for the treatment of chronic pain.

The Company’s two current CA8* gene therapy programs are in preclinical development for treatment of patients suffering from erythromelalgia, a life-long heritable chronic pain condition representing an orphan drug disease with no approved therapy, and chronic osteoarthritis knee pain, affecting a large number of patients that is often treated with opioids due to the lack of good alternatives, thus contributing to the ongoing opioid crisis.

For more information, visit [adolore.com](#).

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
833-475-8247
adolore@jtcir.com